Podcast
The Uromigos
Hosted by The Uromigos · EN
Broadcasting the latest developments in GU cancer
Hosted by Brian Rini and Tom Powles
Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
492episodes
Episodes
Newest firstAll episodes
Episode 499: APCCC 2026 - Radioligands
4w ago00:37:25Tap to summarizeThis session from APCCC 2026 features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in current practices, challenges, and future directions in radiopharmaceuticals.
Transcribe →Episode 498: APCCC 2026 - mCRPC
4w ago00:21:30Tap to summarizeThis APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-driven therapy, and emerging treatment options.
Transcribe →Episode 497: Reflections on the capivasertib ODAC
4w ago00:21:15Tap to summarizeThis podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.
Transcribe →Episode 496: APCCC 2026 - mHSPC Landscape
4w ago00:26:53Tap to summarizeRob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.
Transcribe →Episode 495: APCCC 2026 - Locally-advanced Prostate Cancer
Apr 3000:31:06Tap to summarizeThis episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment decisions.
Transcribe →Episode 494: Duration of EVP in Multiple Urothelial Cancer Settings / Paper of the Month PPARG Inverse Agonist
Apr 2700:40:05Tap to summarizeMatt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.
Transcribe →Episode 493: The Role of Chemotherapy in mHSPC
Apr 1300:47:23Tap to summarizeIn the world of prostate cancer treatment, chemotherapy's role, especially in metastatic hormone-sensitive cases, remains a topic of much discussion and evolving understanding. In this podcast, we delve into the insights shared during a recent conversation with Dr. Deepak Kilari, a GU Medical Oncologist, exploring the nuances of chemotherapy in this context. We discuss key trials, shifting definitions of disease volume, and the implications for treatment decisions.
Transcribe →Episode 492: Novel Biomarkers and Targets in Germ Cell Tumors
Apr 600:33:25Tap to summarizeThis podcast features Dr. Mike Glover from MDACC discussing recent advances in germ cell tumor research, focusing on novel biomarkers like microRNA and ctDNA, and emerging therapies targeting Claudin-6. The conversation explores how these innovations could transform diagnosis, prognosis, and treatment strategies.
Transcribe →Episode 491 Uromigos Japan: ASCO GU26速報！前立腺がん&腎がん
Apr 100:33:49Tap to summarize前立腺がんはPEACE-3 final OSの結果について、腎がんはLITESPARK-011/022試験の解釈から実臨床への影響まで、現地での反応も含めて語り尽くします。
Transcribe →Episode 490: Systemic Therapy Only in Patients wtih MIBC
Mar 3000:48:18Tap to summarizeLaura Bukavina, Tyler Stewart and Amanda Nizam join Brian and Tom to discuss and debate a new clinical trial exploring EVP in MIBC with omission of cystectomy of clinical CR patients
Transcribe →